18 views 0 likes

Dr. CCHMC Pediatric Surgery

GCMD Space · View profile →

Update Course Rewind: MMP-7 & Biliary Atresia Diagnosis 2024

Video Published 2025-03-04 Updated 2026-08-01

Timestops (4)

Practice-Changing Ideas in Biliary Atresia

Case Presentation and Diagnostic Challenge

Timing Impact and Network Data

Conclusions on Early Diagnosis Importance

Topic Overview

A pediatric surgery update course presentation on using matrix metalloproteinase-7 (MMP-7) as a diagnostic biomarker for biliary atresia. The discussion emphasizes that timely diagnosis and early Kasai portoenterostomy—ideally before 45 days of life, with some centers targeting 30 days—significantly improves native liver survival. MMP-7 was identified and validated as a diagnostic tool to expedite workup and reduce delays associated with traditional imaging studies like HIDA scans, which can add 5 days to the diagnostic process. The presentation includes a clinical case example and references multi-center registry data showing that for every 10-day delay in treatment, outcomes worsen by 20%.

Key Takeaways

MMP-7 biomarker expedites biliary atresia diagnosis, cutting ~5 days vs HIDA scan—critical when every 10-day delay worsens outcomes 20% (2:50)
Target Kasai portoenterostomy before 45 days of life (ideally <30 days) to maximize native liver survival and reduce transplant need (5:03)
Direct bilirubin >1 mg/dL at newborn discharge is highly sensitive for biliary atresia; early screening enables timely referral (5:37)
MMP-7 validated in multi-center studies but assay cutoffs still evolving; sensitivity good though not perfect for all cases (4:22)

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Speaker 1 — host
Em Goddy — host
Greg Tea — guest

Chapters

0:01Introduction and Update Course Overview — Introduction to the 12th annual update course in pediatric surgery at Cincinnati Children's, explaining the new classification system for practice-changing ideas (green circle, blue square, black diamond) and introducing Dr. Greg Tea's presentation on MMP-7 in biliary atresia diagnosis.
0:53Clinical Case and Diagnostic Challenge — Presentation of a 38-day-old patient with persistent jaundice and clay-colored stools, illustrating the diagnostic challenge of distinguishing biliary atresia from other causes of neonatal cholestasis and the importance of early intervention.
2:32MMP-7 Discovery and Validation — Description of how MMP-7 was identified by Dr. Georgia Bezarra through proteomic screening of Children's Network registry patients, and subsequently validated in mainland China where biliary atresia incidence is higher and early intervention is critical.
4:26Timing of Kasai and Clinical Outcomes — Discussion of institutional protocols for performing Kasai within 7 days of presentation, evidence showing improved outcomes when Kasai is performed before 45 days, and the role of newborn screening in earlier detection.
5:44Conclusion and Key Takeaways — Summary of the importance of timely biliary atresia diagnosis, the role of MMP-7 as an evolving biomarker, and the goal of performing Kasai before 45 days (or 30 days when possible) to improve native liver survival.

Key claims

0:53Timely diagnosis of biliary atresia is critical to prolong native liver survival — Greg Tea
1:11The key to treating biliary atresia is making an early diagnosis — Em Goddy
1:16MMP-7 was identified about 10 years ago as a diagnostic biomarker for biliary atresia by Georgia Bezarra's lab — Em Goddy
1:37The sooner the Kasai is done, the more likely native liver will be saved — Em Goddy
2:47Cincinnati Children's stopped doing HIDA scans about 25 years ago — Greg Tea
2:50HIDA scan adds about 5 days to the diagnostic workup — Greg Tea
2:55Data from a Midwest study shows that for every 10 day delay in treatment, outcomes worsen by 20% — Em Goddy
3:17The Children's Network is a national consortium of about 14 centers where all cholestatic liver disease children are enrolled in a registry — Greg Tea
3:32Dr. Bezarra screened about 1000 proteins and found 70 or so that were elevated in the biliary atresia population, of which MMP-7 was the most clear — Greg Tea
3:44Within the Children's Network, biliary atresia disease frequency is low, with only 200 to 300 cases per year — Em Goddy
3:57The incidence of biliary atresia is higher in the Far East — Greg Tea
4:01Dr. Bezarra validated MMP-7 findings in just 2 years through a study in mainland China where biliary atresia frequency is much higher — Em Goddy
4:10In China, if biliary atresia patients don't get early Kasai, living donor liver transplant is their only option and it's not readily available, so those kids face a mortality risk — Greg Tea
4:22MMP-7 is now a validated biomarker for biliary atresia — Em Goddy
4:26MMP-7 is not perfect; sensitivity is pretty good but cutoffs vary because the assay is still evolving — Greg Tea
4:44Cincinnati Children's commitment is to perform Kasai within 7 days of patient presentation if they have biliary atresia — Greg Tea
4:52Children's Network data showed that the average age of a biliary atresia patient going through Kasai in North America was around 75 days — Em Goddy
5:03A European study showed that if Kasai is done before 45 days, it reduces the incidence of transplant need in that patient population — Greg Tea
5:22A Kasai portoenterostomy done before 45 days is the goal — Greg Tea
5:27Cincinnati Children's will do Kasai before 30 days if diagnosis can be established — Greg Tea
5:37More and more nurseries are screening newborns at discharge, and a direct bilirubin over 1 in the newborn period is very sensitive for biliary atresia — Greg Tea

Cases discussed

1:4238-day-old infant with persistent jaundice initially attributed to physiologic jaundice

Open questions

What are the optimal MMP-7 cutoff values for biliary atresia diagnosis as the assay continues to evolve?
How can the diagnostic workup be further streamlined to achieve the 30-day Kasai target more consistently?

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Written for:

38-Day-Old with Persistent Jaundice: When Physiologic Becomes Pathologic

The patient case from this episode, retold from presentation to outcome with the decisions made along the way. Written by Kai from the episode transcript and reviewed before publishing.

For specialists · Case narrative · AI-written, human-reviewed

Presentation

A 38-day-old infant presented with persistent jaundice 0:53. The child had passed meconium on the first day of life and was gaining weight appropriately 0:53. The pediatrician initially attributed the jaundice to physiologic jaundice of the newborn 0:53. When the jaundice persisted and the stool became clay-colored, laboratory results returned consistent with biliary atresia 0:53. The infant was referred to hepatology, who initiated the diagnostic workup 0:53. Ultrasound findings were described as "pretty classic" for biliary atresia 0:53.

The Decision Point

With an ultrasound suspicious for biliary atresia in hand, the team faced the diagnostic pathway question that defines institutional practice patterns 0:53. The traditional approach includes hepatobiliary scintigraphy — the HIDA scan — to assess biliary excretion 2:47. But Cincinnati Children's stopped doing HIDA scans about 25 years ago 2:47. The reason is temporal: a HIDA scan adds about 5 days to the diagnostic workup 2:50, and data from a Midwest study shows that for every 10-day delay in treatment, outcomes worsen by 20% 2:55.

The alternative is to proceed directly to operative cholangiogram or exploratory laparotomy based on clinical presentation, laboratory findings, and imaging 2:47. This compresses the diagnostic timeline but requires confidence in the pre-operative assessment 2:50 2:55. The calculus changes when a validated biomarker enters the algorithm 1:16. MMP-7, identified about 10 years ago by one of the discussants' lab 1:16, emerged from screening approximately 1000 proteins in cholestatic infants enrolled in the Children's Network — a national consortium of about 14 centers where all cholestatic liver disease children are enrolled in a registry 3:17. Of the 70 or so proteins elevated in the biliary atresia population, MMP-7 was the most clear 3:32. Validation came rapidly through a study in mainland China, where biliary atresia frequency is much higher than in North America 4:01. In that population, early Kasai is not just preferred but essential: if biliary atresia patients don't get early Kasai, living donor liver transplant is their only option and it's not readily available, so those kids face a mortality risk 4:10.

MMP-7 is now a validated biomarker for biliary atresia 4:22, though it is not perfect — sensitivity is pretty good but cutoffs vary because the assay is still evolving 4:26. The practical question is whether MMP-7 can replace or abbreviate the traditional workup enough to move the needle on surgical timing 4:22 4:26.

What the Team Did

Cincinnati Children's commitment is to perform Kasai within 7 days of patient presentation if they have biliary atresia 4:44. This stands against the Children's Network data showing that the average age of a biliary atresia patient going through Kasai in North America was around 75 days 4:52. A European study showed that if Kasai is done before 45 days, it reduces the incidence of transplant need in that patient population 5:03. The stated goal is a Kasai portoenterostomy done before 45 days 5:22; Cincinnati Children's will do Kasai before 30 days if diagnosis can be established 5:27.

The 38-day-old infant in this case was already beyond the 30-day threshold but well within the 45-day window 0:53 5:27. The ultrasound was classic 0:53. The clinical picture was consistent 0:53. The team's approach reflects the institutional commitment to move quickly once biliary atresia is suspected 4:44.

Outcome

The discussants did not report the outcome of this case.

What This Case Changes

The transferable judgment is about time 1:37 2:55. The sooner the Kasai is done, the more likely native liver will be saved 1:37. Every diagnostic step that adds days without adding certainty is a step worth questioning 2:50 2:55. More and more nurseries are screening newborns at discharge, and a direct bilirubin over 1 in the newborn period is very sensitive for biliary atresia 5:37. When that screen is positive, when the stool is acholic, when the ultrasound is classic, the question is not whether to operate but how quickly you can get there 0:53 5:37. MMP-7 does not replace clinical judgment, but it shortens the interval between suspicion and action 4:22 4:26. In a disease where outcomes worsen by 20% for every 10-day delay 2:55, that interval is the entire game.

Takeaways from this story

HIDA scan adds 5 days to workup; for every 10-day delay, biliary atresia outcomes worsen by 20%
MMP-7 is validated for biliary atresia diagnosis but cutoffs vary as the assay evolves
Kasai before 45 days reduces transplant incidence; Cincinnati targets 7 days from presentation to OR
Direct bilirubin >1 in newborn period is very sensitive for biliary atresia; nurseries increasingly screen at discharge

MMP-7 in Biliary Atresia: Why Speed Matters More Than Certainty

The episode's main topic retold as a plain-language walkthrough — what it is, why it matters, and what the speakers concluded. Written by Kai from the episode transcript and reviewed before publishing.

For the care team · Explainer · AI-written, human-reviewed

The Problem That Made This Necessary

Biliary atresia exists in a diagnostic no-man's-land 0:53. It presents like a dozen other causes of neonatal cholestasis, but unlike most of them, it has a narrow window for effective intervention 1:37. A pediatrician seeing persistent jaundice and acholic stools in a six-week-old faces a long differential — idiopathic neonatal hepatitis, Alagille syndrome, metabolic disorders, infection — and the traditional workup (ultrasound, HIDA scan, serial labs, subspecialty consultation) burns days while the clock runs against the child's native liver 2:50. The core tension is not diagnostic uncertainty; it is diagnostic delay 2:55. Every ten days lost worsens outcomes by 20% 2:55. The Kasai portoenterostomy works best before 45 days of life 5:03, but the average North American patient does not reach the operating room until 75 days 4:52. This gap — between when diagnosis is possible and when it actually happens — is what MMP-7 was developed to close 4:22.

The Core Clinical Problem

Biliary atresia is a progressive obliteration of the extrahepatic bile ducts 0:53. Without surgical drainage, affected infants develop cirrhosis and require liver transplantation or face mortality 0:53. The Kasai procedure — a portoenterostomy that connects a patent portion of the biliary tree directly to a Roux limb — can restore bile flow and preserve the native liver, but only if the ducts have not yet been destroyed 0:53. The earlier the operation, the better the chance of long-term native liver survival 0:53 1:37. The problem is not that biliary atresia is hard to diagnose once you suspect it; the problem is that suspicion arrives late, and traditional confirmatory tests add days to a timeline measured in weeks 2:50 2:55.

Cincinnati Children's stopped performing HIDA scans for this indication 25 years ago because the test added five days to the workup without changing management 2:47 2:50. If the ultrasound is suggestive and the clinical picture fits, they proceed directly to exploration 2:47. Their institutional commitment is to operate within seven days of presentation if biliary atresia is confirmed 4:44. They will operate before 30 days if the diagnosis can be established that early 5:27. This aggressive timeline is not standard everywhere, and it requires a biomarker that can be drawn, resulted, and acted upon quickly 4:22.

How MMP-7 Works

Matrix metalloproteinase-7 is a protease elevated in the serum of infants with biliary atresia 3:17. It was identified through proteomic screening of samples from the Children's Network, a national registry of pediatric cholestatic liver disease across 14 centers 3:17. One of the discussants described screening approximately 1,000 proteins and finding 70 elevated in biliary atresia patients; MMP-7 was the clearest signal 3:32. The initial cohort was small — biliary atresia incidence in North America is low, with only 200 to 300 cases per year across the entire network 3:44 — so validation required a larger population 3:57. The team partnered with investigators in mainland China, where biliary atresia incidence is higher 3:57, and validated the biomarker in just two years 4:01. In that setting, early Kasai is not just preferred but essential; living donor liver transplantation is not readily available, and delayed diagnosis carries mortality risk 4:10.

MMP-7 is now a validated biomarker 4:22, but it is not perfect 4:26. Sensitivity is good, but cutoff values vary across studies because the assay is still evolving 4:26. Different labs use different platforms, and there is not yet a universally standardized threshold 4:26. This means MMP-7 functions best as a triage tool rather than a definitive test 4:22. A high value in a jaundiced infant with acholic stools and a suspicious ultrasound accelerates referral and surgical evaluation 4:22. A low value does not rule out biliary atresia, but it may justify a more measured workup 4:26.

Where Practice Is Contested

The goal of performing Kasai before 45 days is supported by European data showing reduced transplant rates when surgery occurs in that window 5:03. Cincinnati's even more aggressive target — 30 days when feasible 5:27 — reflects institutional experience but is not universal practice 4:44 5:27. Some centers still incorporate HIDA scans or pursue liver biopsy before proceeding to laparotomy 2:47 2:50. The trade-off is between diagnostic certainty and time 2:50 2:55. MMP-7 shifts that calculus by providing an additional data point early in the workup, but it does not eliminate the need for clinical judgment 4:22 4:26. The assay is evolving, cutoffs are not standardized, and no single test replaces the integration of history, exam, imaging, and labs 4:26.

When to Involve This Team

Any infant with conjugated hyperbilirubinemia beyond two weeks of life warrants evaluation 5:37. Direct bilirubin greater than 1 mg/dL in the newborn period is highly sensitive for biliary atresia, and more nurseries are now screening at discharge 5:37. If the infant has acholic stools, persistent jaundice, and suggestive ultrasound findings, refer immediately to a center with pediatric hepatology and surgical expertise in biliary atresia 4:44 5:27. Do not wait for a HIDA scan 2:47 2:50. The window for effective Kasai is narrow, and every week of delay reduces the chance of preserving native liver function 2:55 5:03. If MMP-7 is available at your institution or the referral center, it can expedite triage, but the clinical picture alone is sufficient to trigger urgent consultation 4:22 4:44.

Takeaways from this story

Every 10-day delay in biliary atresia treatment worsens outcomes by 20%; traditional workup steps like HIDA scans can add 5 days.
MMP-7 is a validated serum biomarker for biliary atresia, though assay cutoffs vary and sensitivity is not perfect.
Kasai performed before 45 days reduces transplant need; some centers target 30 days when diagnosis can be established early.
Direct bilirubin >1 mg/dL in newborns is highly sensitive for biliary atresia and should trigger immediate hepatology referral.

Keywords

biliary atresia neonatal jaundice physiologic jaundice cholestatic liver disease idiopathic cholestasis Kasai portoenterostomy HIDA scan ultrasound living donor liver transplant proteomic screening Cincinnati Children's Hospital Medical Center Children's Network mainland China study sites

Hashtags

#BiliaryAtresia #PediatricSurgery #KasaiProcedure #NeonatalJaundice #PediatricHepatology

Transcript

Global Cat MD along with Cincinnati Children's Hospital sharing knowledge to improve child health around the globe. Hello pediatric surgery family. I'm Em Goddy from Cincinnati Children's Hospital Medical Center. Our 12th annual update course in pediatric surgery was held past August. In this video series, we'll recap the sessions and share the main highlights with you. This year, we introduced a new approach to classify practice changing ideas at our update course. Presentations now fall into three categories green circle for established practice, blue square for promising newer practice, and. Black Diamond for early adopter practice only. Here, Doctor Greg Tea, the surgical director of the liver transplantation program at Cincinnati Children's, will explain the use of MMP 7 as a diagnostic tool in biliary atresia. What we're gonna try to touch on is a concept which is a timely diagnosis of biliatresia is critical to prolong the native liver survival. Challenge, of course, as we all face is. That oftentimes these kids come in late. They take a little bit of time to work up. As a result, we are offering surgery at later and later stages. So the key to treating biliaryresia is making an early diagnosis. And this is where this biomarker that really came out of Georgia Bezarra's lab, my, my research mentor, he identified MMP 7 about 10 years ago as a diagnostic biomarker for biliary atresia. And this all ties to this critical concept that I think we all know, but we don't necessarily integrate, which is you gotta get your casa done as soon as possible. The sooner and sooner you get it done, the more likely you'll save the native liver. So this actually was a little guy who showed up just a couple of weeks ago on our service here, a 38 day old child, has a little bit of jaundice, passed meconium on the first day. He's gaining weight, pediatrician says, oh, it's physiologic jaundice of a newborn. But then the jaundice persists, his stool is clay colored, and his lab results are consistent with biliarytresia. This is when things start to escalate. We then refer them into a hepatologist who then starts a workup. And of course, they'll get an ultrasound here, and in this particular case, it had pretty classic findings for biliotresia. The challenge pediatricians face is the differential diagnosis for neonatal jaundice, which includes a long list of potential causes. The key is to distinguish BA from other non physiologic cholestatic jaundice conditions so that we can get our cass done at an earlier and earlier stage. So we have a patient like this and have an ultrasound that's suspicious for biliary atresia. What are you going to do? Those of us who are doing CSIS, what is your decision making here? All of those options are actually correct because it depends on your institution, right? At our institution, we stopped doing HIDA scans about 25 years ago. The challenge that we face with the, uh, a HIDA scan is it adds about 5 days. To this study and data from a recent Midwest study shows that for every 10 day delay in treatment, outcomes worsen by 20%, but it is one of those things where the earlier we can intervene, the better off we'll be. And so this translates to some work that led to this MMP7 study. So about 10 years ago, Georgia took on some data from the Children's Network. Children's Network is a national consortium of about 14 centers in which all the cholestatic liver disease children were enrolled in the registry, and Doctor Bizarra took about 70 or so patients from that, some who had biliary resia, some had idiopathic cholester. Thesis and did some protein mix on that. And he screened about 1000 proteins and they actually found 70 or so that were elevated in the VA population, of which MMP 7 was the most clear. The challenge he faced was that even within the children's network, the disease frequency is low, with only 200 to 300 cases per year. This made it very difficult to conduct another study for validation. Well, this is where he took advantage of the incidences being higher in the Far East. Doctor Baizara was able to validate the findings in just 2 years through a study conducted in mainland China, where the frequency of biliaryresia is much higher. And of course, they really strive to get those kids a cassiah very early because if they don't, living donor liver transplant is their only option and it's not readily available. And so those kids face a mortality risk. So MMP 7 is not. A validated biomarker for biliary atresia. It's not perfect. And actually, if you just look on the table here, the sensitivity is pretty good, but the cutoffs that the different teams used vary because it's an assay that's still evolving in front of our eyes and depending on how you do it. This all leads to the next important question when will you perform the CASAi procedure? Our commitment to the patients who come to our institution is within 7 days of them showing up. If they have it, they're in the OR. Here is a study from the Children's Network in which they showed that the average death of a biliary tresia patient going through Kasai in North America was around 75 days. This one came from Europe, where they actually showed that if you did your Kasai before 45 days, you'd actually reduce the incidence of transplant need in that patient population. All of this is driving the integration of MMPC. 7 into the diagnostic process, allowing for earlier diagnosis and getting patients to a CASA procedure as soon as possible. And this is really the last point, which is a Kasai port neurostomy done before 45 days is the goal. We actually will do it before 30 days if we can establish a diagnosis because nowadays, more and more nurseries are screening their their kids at discharge. And if you have a direct bilirubin over. One in the newborn period, that's also very sensitive for biliaryresia, so those kids get plugged into GI teams sooner and sooner. In conclusion, timely diagnosis of biliarytresia is vital for native liver survival, as early intervention through the Kasai procedure greatly improves outcomes. MMP 7 has been validated as a biomarker to aid in earlier diagnosis, though it's IA continues to evolve. Research highlights the importance of performing the CASAI procedure within 45 days, with some institutions striving for a 30 day target to reduce the need for transplants and enhance survival rates. Thank you for watching this video. Global Cat MD along with Cincinnati Children's Hospital, sharing knowledge to improve child health around the globe.

Comments

Loading comments…